Nenad Grmusa

Amministratore Delegato presso DEM BioPharma, Inc.

Health Technology

Profilo

Nenad Grmusa is currently the Chief Executive Officer & Director at DEM BioPharma, Inc. He previously served as an Outside Director at Chordia Therapeutics, Inc.

Posizioni attive di Nenad Grmusa

Società	Posizione	Inizio
DEM BioPharma, Inc. DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.	Amministratore Delegato	22/09/2022

Tutte le posizioni attive di Nenad Grmusa

Precedenti posizioni note di Nenad Grmusa

Società	Posizione	Fine
CHORDIA THERAPEUTICS INC.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Nenad Grmusa

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Nenad Grmusa

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
CHORDIA THERAPEUTICS INC.	Health Technology

Aziende private	1
DEM BioPharma, Inc. DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.	Health Technology